2026 Assessment of Major Markets for Common Warts: Emerging Therapies Target HPV and Wart Recurrence
Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Common Warts - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The common warts market across the seven major markets (7MM)-the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan-was valued at approximately USD 1 billion in 2025. Market growth through 2036 is expected to be supported by a substantial patient population, frequent recurrence, repeat treatment demand, and the development of targeted immunotherapeutic and antiviral therapies.
Clinical burden is highest among children, adolescents, and immunocompromised individuals, while transmission through direct contact and contaminated surfaces supports continued incidence in schools, households, and other communal environments.
Common Warts Market Size and Forecast
The report provides an evidence-based assessment of common warts epidemiology, treatment practices, market size, therapy uptake, pricing, reimbursement, and competitive dynamics. It evaluates historical and forecast patient trends, therapy-specific revenue, market share, peak patient share, and commercial opportunities across the 7MM.
Common Warts Epidemiology and Patient Burden
Approximately 15.06 million prevalent common warts cases were estimated across the 7MM in 2025. School-aged children carry a particularly high burden, with prevalence increasing during the school years and generally peaking between 12 and 16 years of age. Immunosuppressed patients are more likely to experience persistent, extensive, or recurrent disease.
Although spontaneous resolution can occur within one to two years, a meaningful proportion of lesions persist or recur. Plantar and periungual lesions frequently require clinical intervention because of pain, functional impairment, cosmetic concerns, or resistance to treatment. The epidemiology forecast examines geographic variation, age-related burden, diagnosis trends, recurrence, and the addressable treatment population through 2036.
Diagnosis and Current Treatment Landscape
Diagnosis is primarily clinical and is based on lesion morphology, distribution, and the identification of thrombosed capillaries. Dermoscopy may assist in recurrent or atypical presentations, while biopsy is generally reserved for diagnostically uncertain or treatment-resistant lesions.
Topical salicylic acid and liquid nitrogen cryotherapy remain the principal first-line treatments because of their accessibility, affordability, and established clinical use. However, prolonged treatment courses, discomfort, multiple office visits, variable clearance, and recurrence can limit adherence and satisfaction.
Electrosurgery, curettage, laser ablation, trichloroacetic acid, and surgical excision may be used for recalcitrant lesions. These interventions can provide rapid lesion destruction but may be associated with pain, scarring, higher costs, and inconsistent recurrence control. Off-label immunotherapeutic approaches, including intralesional Candida antigen, are receiving increased attention for patients with multiple, recurrent, or treatment-resistant warts.
No FDA-approved prescription therapy is currently indicated specifically for common warts. This treatment gap creates a significant opportunity for standardized therapies that improve lesion clearance, reduce recurrence, simplify administration, and address HPV-associated disease mechanisms.
Key Common Warts Market Drivers
Common Warts Pipeline and Competitive Landscape
The emerging common warts pipeline includes CANDIN, YCANTH (VP-102), KNP2002, and other early-stage programs. Development strategies increasingly emphasize immunologic clearance, controlled topical administration, antiviral activity, improved tolerability, and more durable outcomes.
CANDIN: Nielsen BioSciences and Maruho
CANDIN is under development as an intralesional immunotherapeutic approach intended to activate cell-mediated immunity against HPV-associated lesions. Nielsen BioSciences advanced the program following encouraging Phase II findings. CANDIN is approved in the United States as a diagnostic skin test for cellular hypersensitivity to Candida albicans, but it is not approved in the United States or Japan for treating common warts.
In October 2025, Nielsen BioSciences announced an expansion of its licensing agreement with Maruho. The agreement granted Maruho exclusive development and commercialization rights for CANDIN in additional Asian territories, supporting broader regional development of the investigational therapy.
YCANTH (VP-102): Verrica Pharmaceuticals and Torii Pharmaceutical
YCANTH is a proprietary drug-device combination containing a controlled 0.7% cantharidin formulation delivered through a single-use applicator. The COVE-1 Phase II study evaluated its safety and efficacy in patients with common warts. Following regulatory discussions with the FDA, Verrica advanced a global pivotal Phase III program, with the first patient dosed in December 2025.
In July 2025, Verrica Pharmaceuticals amended its collaboration and licensing agreement with Torii Pharmaceutical to support the global Phase III common warts trial. The program is designed to assess whether standardized cantharidin delivery can produce more consistent outcomes than traditional compounded or procedurally administered approaches.
KNP2002: KinoPharma and Iwaki Seiyaku
KNP2002 represents another emerging program within the common warts pipeline. In August 2025, Iwaki Seiyaku reported results from a Phase II clinical study assessing the safety and efficacy of an ointment formulation for verruca vulgaris developed with KinoPharma.
Key companies active in the common warts therapeutics market include Nielsen BioSciences, Maruho, Verrica Pharmaceuticals, Torii Pharmaceutical, KinoPharma, and Iwaki Seiyaku.
Common Warts Unmet Medical Needs
Drug Class and Therapy Uptake Outlook
Topical keratolytics are expected to retain substantial use because of their low cost, over-the-counter availability, and familiarity. Cryotherapy should also maintain strong adoption in dermatology and primary care, particularly for symptomatic or persistent lesions. Nevertheless, both approaches face limitations related to treatment duration, pain, adherence, and recurrence.
Intralesional immunotherapies are anticipated to gain greater use in patients with multiple or refractory lesions. Pipeline therapies such as CANDIN, YCANTH, and KNP2002 may achieve gradual uptake as clinical evidence develops and physicians gain experience with new treatment mechanisms. Commercial performance will depend on efficacy, safety, treatment frequency, route of administration, pricing, reimbursement, and differentiation from inexpensive established therapies.
Regional Common Warts Market Outlook
The United States is expected to remain the largest common warts market because of its established dermatology infrastructure, high treatment utilization, procedural volume, and potential for early adoption of advanced therapies. Germany, France, Italy, Spain, and the United Kingdom are projected to show steady growth as access to dermatologic care and awareness of treatment alternatives improve. Japan also represents an important opportunity for licensed pipeline products and regional development partnerships.
Market Access, Pricing and Reimbursement
The report assesses country-specific access conditions, reimbursement pathways, cost-effectiveness, out-of-pocket expenses, patient-support programs, and payer considerations. Pricing analysis includes current treatment costs and analogue-based assessments for emerging therapies. Because established salicylic acid products and procedural options are relatively inexpensive, developers of premium therapies will need to demonstrate measurable benefits in clearance, recurrence prevention, convenience, tolerability, or reduced healthcare utilization.
Report Scope and Strategic Value
Primary research includes insights from more than 10 key opinion leaders and subject-matter experts across major markets. Expert perspectives help validate epidemiology, prescribing patterns, treatment adherence, access barriers, therapy switching, pipeline potential, and anticipated adoption of emerging common warts treatments.
Common Warts Market Outlook to 2036
The common warts treatment market is gradually shifting from conventional lesion destruction toward targeted, immune-mediated, and mechanism-based therapies. Salicylic acid and cryotherapy will remain important standards of care, but their clinical limitations leave room for therapies offering durable clearance, lower recurrence, improved tolerability, and convenient administration.
High disease prevalence, recurrent treatment demand, and the absence of specifically approved prescription therapies support continued commercial opportunity. If late-stage candidates generate compelling efficacy and safety evidence, CANDIN, YCANTH, KNP2002, and other pipeline products could reshape the common warts market through 2036 and establish new treatment options for patients with persistent, multiple, or refractory lesions.
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/euguj9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.